REstoration of Communication and LAnguage With Intracortical Microelectrodes (RECLAIM)
Early Feasibility Study of the Restoration of Communication and Language With Intracortical Microelectrodes (RECLAIM) System
The purpose of this study is to investigate the safety and feasibility of using distributed intracortical recordings from the language network to decode intended language output in individuals with severe communication impairment due to severe communication impairment resulting from amyotrophic lateral sclerosis (ALS), locked-in syndrome, and brain injury including from stroke.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Nitin Tandon, MD
- Número de telefone: (713) 500-5456
- E-mail: Nitin.Tandon@uth.tmc.edu
Estude backup de contato
- Nome: Eliana Klier, PhD
- Número de telefone: (713) 500-5442
- E-mail: Eliana.Klier@uth.tmc.edu
Locais de estudo
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- The University of Texas Health Science Center at Houston
-
Investigador principal:
- Nitin Tandon, MD
-
Contato:
- Nitin Tandon, MD
- Número de telefone: (713) 500-5456
- E-mail: Nitin.Tandon@uth.tmc.edu
-
Contato:
- Eliana Klier, PhD
- Número de telefone: (713) 500-5442
- E-mail: Eliana.Klier@uth.tmc.edu
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Clinical diagnosis of ALS, locked-in syndrome, or stroke
- ALS - ALS patients who in the opinion of the treating neurologist have at least 3 years of survival
- Locked-in Syndrome as a result of brain-stem stroke or traumatic brain-stem injury - patients who in the opinion of the treating neurologist have at least 3 years of survival
- Stroke (either ischemic or hemorrhagic) - for patients with prior stroke, the original cause of the stroke (e.g., arteriovenous malformation, carotid stenosis, atrial fibrillation, heart disease, hypertension) must have been addressed and the patient must not have had a recurrent stroke at least within the prior 12 months
-
ALS diagnosis, stroke, or Locked-in syndrome (LIS) etiology onset occurred at least one year prior to enrollment
-
Minimal communication ability as assessed by a speech-language pathologist
- unable to produce more than 10 total unique intelligible words when reading the Rainbow Passage and Grandfather Passage, and
- unable to write or type more than 10 unique words from a dictated list of 20 words.
-
Limited upper limb strength based on the Medical Research Council Scale for Muscle Strength
- ≤3/5 strength throughout both arms for those with non-progressive conditions (stroke or traumatic brain-stem injury)
- ≤4/5 strength throughout both arms for those with ALS
i. For patients with 4/5 strength, they must have a documented decline in speech or upper extremity function in the preceding 12 months.
-
Has a means of communication sufficient to enable understanding of research protocol and provide consent (e.g. eye blinks or eye movements, use of assistive technology). Thus patients are severely impaired with regards to naturalistic communication, but able to make decisions regarding their own care
-
Ability to understand and comply with study session instructions
-
Must live within a 90-minute drive of study site and willing to travel to study site up to three days per week for duration of the study
-
Has a stable psychosocial support system with caregiver capable of providing care during post-operative periods and monitoring participant throughout the study
-
Stable ventilator status - ventilator requirements have not changed over prior 6 months and ventilator status does not impose additional substantial risks to subject participation, including travel to the investigation site
Exclusion Criteria:
- Psychiatric conditions including current diagnosis of major psychiatric illness, significant cognitive impairment (based on a neuropsychological assessment by a clinical psychologist), suicidal ideation with intent/plan. [Columbia-Suicide Severity Rating Scale (C-SSRS) Categories 4-5)] or suicidal behavior within 12 months, or substance abuse/narcotic/alcohol dependence within 12 months.
- Neurological disorders including current diagnosis of epilepsy, abnormal pre-surgical neuroimaging precluding safe implant placement (per neurosurgical team), prior ipsilateral craniotomy, or hydrocephalus with or without ventricular shunt.
- Implanted electronic devices including pacemakers, cardiac defibrillators, spinal cord stimulators, vagal nerve stimulators, deep brain stimulators, or cochlear implants.
- Cardiovascular disorders including acute myocardial infarction (MI) or cardiac arrest within 6 months, significant cardiovascular impairment contraindicating surgery.
- Hematological disorders requiring chronic anticoagulation and medical contraindication to discontinuing anticoagulant medications perioperatively.
- Dermatological conditions causing excessive skin sloughing, poor wound healing, existing scalp lesions, or skin breakdown.
- Infectious/immunological conditions including active infections, unexplained fever, HIV infection, ongoing chronic infections, medical conditions predisposing to high infection risk, chronic steroid or immunosuppressive therapy, or active cancer within 1 year requiring chemotherapy.
- Medical contraindications including conditions contraindicating chronically implanted devices (osteomyelitis, diabetes, hepatic failure, autoimmune disease/disorders with associated altered immune responses) or other chronic unstable medical conditions interfering with participation.
- Surgical contraindications including medical contraindications to general anesthesia, craniotomy, or surgery; significant pulmonary, metabolic, or renal impairments making surgical procedure unsafe.
- Other exclusions including pregnancy (confirmed by blood test), nursing, inadequate contraception, correction vision worse than 20/100, limited English proficiency, or concurrent participation in device/drug trials.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: RECLAIM System
|
6 microelectrode grids will be implanted within the dominant hemisphere, placed across key speech and language cortical regions. The device will be kept implanted for up to 5 years and study sessions will be conducted 3-5 times per week |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Safety as assessed by the number and type of adverse events that occur
Prazo: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety as assessed by the number of participants with device explanted
Prazo: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
|
|
Safety as assessed by the number of participants with Serious Adverse Events that result in death or permanently increased disability
Prazo: From time of implant to one year post-implant
|
From time of implant to one year post-implant
|
|
|
Effectiveness of the device as assessed by the Word error rate (WER)
Prazo: Every three months for the first two years post-implant
|
Every three months for the first two years post-implant
|
|
|
Effectiveness of device as assessed by the Phoneme error rate (PER)
Prazo: Every three months for the first two years post-implant
|
Every three months for the first two years post-implant
|
|
|
Effectiveness of the device as assessed by the Bilingual Evaluation Understudy (BLEU) Score
Prazo: Every three months for the first two years post-implant
|
BLEU (Bilingual Evaluation Understudy) quantifies, on a range of 0-1, the overlap between the decoded text and the reference text based on matching n-grams. Higher BLEU scores indicate that the decoded output more closely matches the reference at the level of local word sequences. |
Every three months for the first two years post-implant
|
|
Effectiveness of the device as assessed by the Bidirectional Encoder Representations from Transformers (BERT) Score
Prazo: Every three months for the first two years post-implant
|
BERT Score compares the semantic similarity (on a range of -1 to 1) between the decoded text sequence and the reference text using a pretrained language model (BERT). Higher scores indicated stronger semantic alignment. |
Every three months for the first two years post-implant
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Transtornos Mentais, Desordem Mental
- Ferimentos e Lesões
- Doenças Neuromusculares
- Doenças Metabólicas
- Manifestações Neurocomportamentais
- Doenças Neurodegenerativas
- Distúrbios do Neurodesenvolvimento
- Trauma Craniocerebral
- Trauma, Sistema Nervoso
- Doenças da Medula Espinhal
- Proteinopatias TDP-43
- Deficiências de Proteostase
- Doença do neurônio motor
- Paralisia
- Quadriplegia
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Sinais e sintomas
- Síndrome de Encerramento
- Derrame
- Lesões cerebrais
- Esclerose Lateral Amiotrófica
- Distúrbios da Comunicação
Outros números de identificação do estudo
Outros números de identificação do estudo
- HSC-MS-26-0020
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .